Hvsen Biotechnology Past Earnings Performance
Past criteria checks 0/6
Hvsen Biotechnology's earnings have been declining at an average annual rate of -50.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 9.8% per year.
Key information
-50.4%
Earnings growth rate
-53.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 9.8% |
| Return on equity | -3.2% |
| Net Margin | -4.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Sep 30
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate
Aug 21Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper
Jun 05Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable
Mar 29Revenue & Expenses Breakdown
How Hvsen Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,121 | -46 | 160 | 52 |
| 30 Jun 24 | 1,007 | -51 | 155 | 52 |
| 31 Mar 24 | 996 | -14 | 155 | 50 |
| 31 Dec 23 | 1,020 | 17 | 155 | 45 |
| 30 Sep 23 | 1,043 | 41 | 129 | 45 |
| 30 Jun 23 | 1,075 | 62 | 122 | 42 |
| 31 Mar 23 | 1,048 | 66 | 115 | 40 |
| 01 Jan 23 | 1,023 | 53 | 113 | 40 |
| 30 Sep 22 | 922 | 40 | 84 | 45 |
| 30 Jun 22 | 857 | 38 | 80 | 49 |
| 31 Mar 22 | 888 | 71 | 83 | 51 |
| 01 Jan 22 | 996 | 133 | 81 | 47 |
| 30 Sep 21 | 1,027 | 173 | 104 | 41 |
| 30 Jun 21 | 1,026 | 199 | 105 | 34 |
| 31 Mar 21 | 956 | 188 | 99 | 31 |
| 31 Dec 20 | 777 | 150 | 91 | 28 |
| 30 Sep 20 | 655 | 130 | 79 | 22 |
| 31 Dec 19 | 427 | 69 | 64 | 21 |
| 31 Dec 18 | 422 | 71 | 79 | 20 |
| 31 Dec 17 | 400 | 88 | 78 | 18 |
| 31 Dec 16 | 258 | 49 | 63 | 13 |
Quality Earnings: 300871 is currently unprofitable.
Growing Profit Margin: 300871 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300871 is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.
Accelerating Growth: Unable to compare 300871's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300871 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Return on Equity
High ROE: 300871 has a negative Return on Equity (-3.21%), as it is currently unprofitable.